Drugs / V938
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04135352 | Nov 2019 → Aug 2022 | metastatic neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V938 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04135352 ↗ |